Hiroyuki Kusuhara
Hongo, 1130033, Japan
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 206 publications
Synthesis Based on Covalent Capture and Release Enables Purification-free Fluorogenic Probe Libraries for Single-Molecule Protease Activity Profiling.
Journal: ACS central science
Published: May 04, 2026
Real-Time Detection of Cardiotoxic Anticancer Drug by Diamond Microsensors in the Skin and Combined Monitoring of Electrocardiogram in Live Rats.
Journal: ACS sensors
Published: February 16, 2026
Baat-Deficient Mice Recapitulate Elevated 7α-Hydroxy-3-Oxo-4-Cholestenoic Acid Observed in a Japanese Patient With BAAT Deficiency.
Journal: Journal of inherited metabolic disease
Published: January 19, 2026
Intracerebral Distribution of Drugs with Diverse Blood-brain Barrier Transport Characteristics: In vivo Analysis using Brain Microdialysis in Cynomolgus Monkeys.
Journal: Pharmaceutical research
Published: September 25, 2025
Integrating renal transporter biomarkers into drug development: Discovery, clinical assessment, and precision medicine.
Journal: Drug metabolism and pharmacokinetics
Published: September 23, 2025
Mitorubin, berberrubine-based compounds that improve mitochondrial function, exhibit cardioprotective effects against age-related cardiac dysfunction.
Journal: npj aging
Published: August 08, 2025
A novel selective stabilizer of the ryanodine receptor 2 prevents stress-induced ventricular arrhythmias without impairing cardiac function.
Journal: British journal of pharmacology
Published: July 30, 2025
Evaluation of Puberulic Acid-Induced Nephrotoxicity Using 3D-RPTEC.
Journal: Biological & pharmaceutical bulletin
Published: June 26, 2025
Quantitative analysis of coproporphyrin and its precursors as endogenous biomarkers for drug-drug interactions involving OATP1B1 and OATP1B3 in monkeys.
Journal: Drug metabolism and disposition: the biological fate of chemicals
Published: April 10, 2025
Predicting OCT2/MATEs-Mediated Drug Interactions in Healthy Volunteers and Patients with Chronic Kidney Disease: Insights from Extended Clearance Concept, Endogenous Biomarkers, and In Vitro Inhibition Studies (Perspectives from the International Transporter Consortium).
Journal: Clinical pharmacology and therapeutics
Published: January 13, 2025
Bridging in vitro and clinical data: Experimental insights into the IC50 variability of dolutegravir as an organic cation transporter 2 inhibitor.
Journal: Drug metabolism and disposition: the biological fate of chemicals
Published: January 09, 2025
Last Updated: 09/26/2026